|Indian Brand Name:||HEPCINAT-LP|
|Manufacturer:||Natco Pharma Ltd.|
|Strength:||SOFOSBUVIR 400mg+LEDIPASVIR 90mg|
|Packaging:||Bottle of 28 Tablets|
HEPCINAT-LP contains polymerase inhibitors which called sofosbuvir and ledipasvir . Hepcinat-LP launched by Natco Pharma Ltd (India) and approved for treatment patients infected with HCV genotypes 1 and 4. Sofosbuvir & Ledipasvir is FDA-approved and EASL recommended treatment protocol for HCV, which does not include interferon or ribavirin. Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.
Never Treated for Hep C
|Ledipasvir + sofosbuvir||Type||Weeks of Treatment||Cure Rate|
Previously Treated for Hep C
|Ledipasvir + sofosbuvir||Type||Cure Rate for 12 weeks||Cure Rate for 24 weeks|
|Ever Treated for Sofosbuvir, peginterferon alfa, and ribavirin, but failed||93%||100%|
Only logged in customers who have purchased this product may leave a review.
© 2015 Copyright by CancerCareMeds